In recent studies, CSF SNAP-25 and Ng levels yielded a high diagnostic accuracy in distinguishing CJD from other neurodegenerative disorders [21–24]; however, no studies have ever evaluated their diagnostic value in the clinical setting (i.e., against other rapidly progressive neurological syndromes) and the influence of the CJD subtype on biomarker levels. This evidence concerns the gene NRGN and Creutzfeldt Jacob disease.